This approach maintains more stable blood levels and may reduce side effects
The staged introduction approach takes longer to implement but provides far more useful information
REDEFINE 1 included 3,417 participants with overweight or obesity but without diabetes (mean age, 47 years
Outstanding liabilities to consider during the development process and commercialization include: Regulatory risk on the need for a cardiovascular outcomes trial
Injectable semaglutide is a weekly subcutaneous injection from a multi-dose vial, $189$289/mo
For patients experiencing significant symptoms, temporarily pausing therapy, maintaining the current dose for an additional 2-4 weeks before advancing, or implementing smaller dose increments when formulation allows, may improve tolerance